Skip to main content

ALS BRAC

Amyotrophic Lateral Sclerosis Biospecimen Resource Access Committee

The Amyotrophic Lateral Sclerosis Biospecimen Resource Access Committee (ALS BRAC) reviews applications for samples from studies of ALS, FTLD, and genetically at-risk for ALS/FTLD.

Submission and Review Dates
Submission and Review Dates
Date SubmittedReviewed by
November 1, 2025 - January 2, 2026 February 5, 2026
January 1, 2026 - February 28, 2026April 3, 2026
March 1, 2026 - May 1, 2026June 4, 2026
May 2, 2026 - July 3, 2026August 6, 2026
July 4, 2026 - August 28, 2026, 2026October 1, 2026
August 29, 2026 - October 29, 2026December 2, 2026
October 30, 2026 - January 1, 2027February 4, 2027

The BRAC committee will assess the applications based on experimental rationale, feasibility/reproducibility of the assays, expertise of the investigator, availability of the institutional resources to support the study, and the statistical analysis of the number of samples required for the hypothesis testing.  Investigators will be notified by email the outcome of the review (i.e. approve, approve upon revisions, or deny) within a week after the review meeting.  Summary statements are released 2-3 weeks after review.  For applications that were ‘approved upon revisions’, investigators will be notified about concerns that would need to be addressed before the application could move forward.  Please note that the ALS/FTD BRAC does not provide funding.

If sample access is approved by the ALS/FTD BRAC, the two possible outcomes are:

  1. If the study has funding, the samples are distributed to the investigator following a virtual meeting to introduce the sample distribution process (“on-boarding”) and after fulfilment by the investigator of additional requirements specified by BioSEND (i.e. MTA, Data Use Agreement, data analysis and sharing plan).  For questions, please contact Rebecca Price, Ph.D.
  2. If the investigator has yet to obtain funding for the study, the BRAC will issue a letter to the applicant documenting provisional access to the samples requested.  This letter can be used to support an application for funding opportunities from the NIH or other organizations.  Conditional approvals will be valid for a period of up to 12 months.

To facilitate scientific rigor and reproducibility, samples for approved applications are shipped blinded (each aliquot is labeled with a Sample ID). The BioSEND team will work with investigators during the onboarding call to create box designs to facilitate blinded analyses. Investigators must return their assay analyses into an appropriate data repository prior to being unblinded by BioSEND.

Barmada, Sami, MD, PhD
Associate Professor
Director, Michigan Brain Bank
University Of Michigan
Ann Arbor, MI 48109
Belzil, Veronique, PhD, MS
Associate Professor
Director, Vanderbilt ALS Research Center
Vanderbilt University
Nashville, TN 37232
Berry, James, MD, MPH
Chief, Division Of ALS And Motor Neuron Diseases
Massachusetts General Hospital
Massachusetts, MA 02114
Bowser, Robert, PhD
Chief Scientific Officer
Barrow Neurological Institute
Phoenix, AZ 85013
Brown, Robert, MD, DPhil
Professor, Donna M And Robert J Manning Chair In Neuroscience
UMass Chang Medical School, Department Of Neurology
Worcester, MA 01605
Dave, Kuldip, PhD
Senior Vice President Of Research
ALS Association
Arlington, VA 22209
Easton, Amy, PhD
Senior Director Of Scientific Programs
Target ALS
New York, NY 10016
Fratta, Pietro, PhD
Professor, Department Of Neuromuscular Diseases
University College London
London, United Kingdom
Gendron, Tania, PhD
Associate Professor, Department Of Neuroscience
Mayo Clinic Jacksonville
Jacksonville, FL 32224
Grunseich, Christopher, MD
Lasker Clinical Research Scholar And Investigator
National Institute Of Neurological Disorders And Stroke
Bethesda, MD 20814
Kolb, Stephen, MD, PhD
Professor Of Neurology, Department Of Neurology
The Ohio State University
Columbus, OH 43221
Oskarsson, Bjorn, MD
Neurologist, Associate Professor, Department Of Neurology
Mayo Clinic
Jacksonville, FL 32224
Schneider, Anja, PhD
Professor, German Research Center For Neurodegenerative Diseases
University Of Bonn
Bonn, Germany
Seyfried, Nicolas, PhD
Professor, Department Of Biochemistry And Neurology
Emory University
Atlanta, GA 30322
Van Blitterswijk, Marka, MD, PhD
Associate Professor, Department Of Neuroscience
Mayo Clinic Jacksonville
Jacksonville, FL 32224
Van Keuren-Jensen, Kendall, PhD
Vice President For Research And Professor
Bioinnovation And Genome Sciences Division
The Translational Genomics Research Institute
Phoenix, AZ 85004
Walk, David, MD, FAAN
Professor And Neuromuscular Medicine Division Director
Department Of Neurology, University Of Minnesota
Minneapolis, MN 55455
Wuu, Joanne, ScM
Research Associate Professor, Department Of Neurology
University Of Miami
Miami, FL 33126
Xie, Sharon, PhD
Senior Scholar, Center For Clinical Epidemiology And Biostatistics
University Of Pennsylvania
Philadelphia, PA 19104

Please note that your application will be shared with BRAC members, NINDS program staff, and BioSEND staff. Access and review of all applications is guided ethical research standards, as described in the Guiding Principles statement and the Confidentiality Agreement.

Coming Soon!

Learn more about the review process
View available samples

Submit Application